Key Takeaways
- Zoetis has entered a definitive agreement to acquire Neogen’s animal genomics business for $160 million.
- The acquisition includes five international laboratories located in the U.S., Brazil, Australia, China, and the United Kingdom.
- The deal aims to enhance the Zoetis Precision Animal Health portfolio by integrating advanced genotyping and data solutions.
- The transaction is expected to close in the second half of 2026, pending regulatory approvals and customary closing conditions.
- The move expands Zoetis’ capabilities in predictive insights and individualized care for livestock and companion animals.
Strategic Expansion for Zoetis
Zoetis (NYSE: ZTS) announced today that it has signed a definitive agreement to acquire the animal genomics business of Neogen Corporation (NASDAQ: NEOG) for $160 million. This cash transaction is subject to customary closing adjustments and aligns with the company’s long-term strategy to lead livestock innovation through advanced genetic data.
By incorporating Neogen’s genomic technologies, Zoetis intends to broaden its existing Precision Animal Health portfolio. The integration is designed to provide livestock producers and veterinarians with more comprehensive data-driven insights to improve animal productivity and sustainability.
Global Laboratory Infrastructure and Reach
Neogen’s genomics division currently serves a global customer base across 120 countries. The business operates five dedicated laboratories in the United States, Brazil, Australia, China, and the United Kingdom, alongside an office in Canada.
The acquisition includes Neogen’s genotyping platform, which utilizes fixed array and sequencing technologies. These tools are currently used to provide genetic testing for U.S. beef and dairy sectors, offering insights into animal health and performance. Zoetis will leverage these existing software solutions to help customers make informed decisions regarding their herds and companion animals.
Leadership Perspectives on Innovation
The acquisition is viewed as a complementary move to bridge the gap between genetic potential and health outcomes. Leadership emphasizes that the deal will provide the scale necessary to enhance individualized care across various species.
“The addition of Neogen’s genomics business strengthens our commitment to advancing animal health through innovation, data, and technology,” said Jamie Brannan, Chief Commercial Officer at Zoetis. “As we continue to grow our leading innovative solutions in Precision Animal Health, this acquisition brings complementary capabilities that expand predictive insights and individualized care, enabling us to deliver added value to customers.”
Zoetis Future Outlook and Integration
Zoetis expects the transaction to conclude in the second half of the 2026 calendar year. Until the closing date, both companies will continue to operate independently. Following the completion of the deal, Zoetis has stated it is committed to a seamless integration process to ensure continuity for employees and customers currently utilizing Neogen’s genomics services.
